RWE

OptimizeRx’s Evidence-Based Physician Engagement Solution Named One of the Most Innovative Products of the Year by PM360

Retrieved on: 
Wednesday, December 29, 2021
Industry, COVID-19, Private Securities Litigation Reform Act, Innovation, HCPS, U.S. Securities and Exchange Commission, RWE, GLOBE, Company, Leadership, CEO, Organization, Regulation, Decision-making, Marketing, Patient, Physician engagement, Intention, Awareness, Adoption, Forward-looking statement, PR, Medical device, Pharmaceutical industry, Management, Public relations

(the Company)(Nasdaq: OPRX),a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced its Evidence-based Physician Engagement solution has been recognized as one of the most innovative products of the year for life sciences by PM360.

Key Points: 
  • (the Company)(Nasdaq: OPRX),a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced its Evidence-based Physician Engagement solution has been recognized as one of the most innovative products of the year for life sciences by PM360.
  • OptimizeRxs Evidence-Based Physician Engagement solution uses the Companys AI-driven Therapy Initiation and Persistence Platform to deliver insights in real time.
  • The editorial staff of PM360 evaluated each submission and selected their picks for the most innovative, regardless of category.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Global Real World Evidence Solutions Market Segment Forecasts 2021-2028: Shift from Volume to Value-Based Care - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 22, 2021
Health, General Health, Salesforce, USD, Service, Temperature, IBM, ServiceNow, Organization, COVID-19, Solution, Leadership, Component, Independent Healthcare Providers Network, Artificial intelligence, COVID-19 datasets, Prevalence, RWE, CAGR, Pharmaceutical industry, Application

The "Global Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, Datasets), End User (Healthcare Payers, Healthcare Providers), Application, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, Datasets), End User (Healthcare Payers, Healthcare Providers), Application, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global real world evidence solutions market size is anticipated to reach USD 66.4 billion by 2028.
  • The key factors driving the real world evidence solutions (RWE) market growth include the favorable government regulations and shift from volume to value-based care.
  • Chapter 3 Real world evidence (RWE) Solutions Market Variables, Trends & Scope

Clarivate Acquires Patient Connect, Furthering Position as a Leading Provider of Patient-Centric Solutions

Retrieved on: 
Wednesday, December 22, 2021
Physician, NYSE, Disease, Patient, Drug discovery, DRG, Pharmacist, HCP, RWD, Acquisition, Forward-looking statement, Intellectual property, Artificial intelligence, Health, Solution, Invention, Intelligence, Decision, RWE, Clarivate, Bachelors of Science (group), Research, Science, Pharmaceutical industry, Risk management, Medical device

LONDON, Dec. 22, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that it has acquired Patient Connect, a provider of patient engagement solutions that enable the measurement of clinical and commercial outcomes and inform the advancement of healthcare. 

Key Points: 
  • Patient Connect patient engagement solutions improve patient outcomes by delivering clinical messaging to physicians and pharmacists at the point of patient contact.
  • Clarivaterealworlddata(RWD)products paired with Patient Connect insights will providelife science companies with global patient journey information.The acquisitionaddresses the increasing need for global personalized data thathelpslife sciencecompanies understand patient populations, supports compliant patient journey analyses andbringslife-saving treatmentsto market.
  • Zoe Baker, Founder and Co-CEO, Patient Connect:"This acquisition serves to provide life science firms with insights to inform the advancement of healthcare through integrated patient journey insights, leveraging Clarivate solutions paired with analytics from Patient Connect.
  • The integration of Patient Connect products with Clarivate assets will further facilitate patient engagement, drive behavioral change and empower healthcare professionals to optimize care."

Clarivate Acquires Patient Connect, Furthering Position as a Leading Provider of Patient-Centric Solutions

Retrieved on: 
Wednesday, December 22, 2021
Physician, NYSE, Disease, Patient, Drug discovery, DRG, Pharmacist, HCP, RWD, Acquisition, Forward-looking statement, Intellectual property, Artificial intelligence, Health, Solution, Invention, Intelligence, Decision, RWE, Clarivate, Bachelors of Science (group), Research, Science, Pharmaceutical industry, Risk management, Medical device

LONDON, Dec. 22, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that it has acquired Patient Connect, a provider of patient engagement solutions that enable the measurement of clinical and commercial outcomes and inform the advancement of healthcare. 

Key Points: 
  • Patient Connect patient engagement solutions improve patient outcomes by delivering clinical messaging to physicians and pharmacists at the point of patient contact.
  • Clarivaterealworlddata(RWD)products paired with Patient Connect insights will providelife science companies with global patient journey information.The acquisitionaddresses the increasing need for global personalized data thathelpslife sciencecompanies understand patient populations, supports compliant patient journey analyses andbringslife-saving treatmentsto market.
  • Zoe Baker, Founder and Co-CEO, Patient Connect:"This acquisition serves to provide life science firms with insights to inform the advancement of healthcare through integrated patient journey insights, leveraging Clarivate solutions paired with analytics from Patient Connect.
  • The integration of Patient Connect products with Clarivate assets will further facilitate patient engagement, drive behavioral change and empower healthcare professionals to optimize care."

Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market

Retrieved on: 
Tuesday, December 21, 2021
Real, Real world data, Patient, Efficiency, Public health, Czech Republic, Growth, Contract research organization, CRO, Acquisition, Health information management, Health, Solution, EDC, Institute, Biotechnology, Federation, Breathing gas, RWE, Research, Clinical trial, Medical device, Public relations, Pharmaceutical industry, EU, EMMS International

ROCKVILLE, Md., Dec. 21, 2021 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Institut Dr. Schauerte, a CRO headquartered in Munich, Germany.  Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-up studies.  It has conducted more than 400 studies across a range of therapeutic areas. 

Key Points: 
  • Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-upstudies.
  • The acquisition of Institut Dr. Schauerte augments Emmes' global reach by expanding the company's presence in Germany and adding new long-term strategic relationships with global biopharma companies.
  • With Institut Dr. Schauerte, Emmes now has more than 1,200 employees.
  • Institut Dr. Schauerte has a 30-year history and deep expertise in the growing field of Real World Evidence (RWE) research.

Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market

Retrieved on: 
Tuesday, December 21, 2021
Real, Real world data, Patient, Efficiency, Public health, Czech Republic, Growth, Contract research organization, CRO, Acquisition, Health information management, Health, Solution, EDC, Institute, Biotechnology, Federation, Breathing gas, RWE, Research, Multimedia, Clinical trial, Medical device, Public relations, Pharmaceutical industry, EU, EMMS International

Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-upstudies.

Key Points: 
  • Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-upstudies.
  • The acquisition of Institut Dr. Schauerte augments Emmes' global reach by expanding the company's presence in Germany and adding new long-term strategic relationships with global biopharma companies.
  • With Institut Dr. Schauerte, Emmes now has more than 1,200 employees.
  • Institut Dr. Schauerte has a 30-year history and deep expertise in the growing field of Real World Evidence (RWE) research.

Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market

Retrieved on: 
Tuesday, December 21, 2021
Clinical trial, RWE, Health, Institute, Federation, Acquisition, Contract research organization, Public health, Investment, Czech Republic, Biotechnology, Research, Solution, Company, Breathing gas, Real, CRO, Real world data, Growth, IDS, Public relations, Pharmaceutical industry, EU, EMMS International

IDS marks the third acquisition for Emmes in the last year and since Behrman's investment in 2019.

Key Points: 
  • IDS marks the third acquisition for Emmes in the last year and since Behrman's investment in 2019.
  • The acquisition of IDS augments Emmes' global reach by expanding the Company's presence in Germany and adding new long-term strategic relationships with global biopharma companies.
  • Grant Behrman, Managing Partner of Behrman Capital, said, "IDS is a highly complementary and additive business that significantly enhances the Emmes platform.
  • Institut Dr. Schauerte has a 30-year history and deep expertise in the growing field of Real World Evidence (RWE) research.

AstraZeneca supports the growth of the C3i Lymphoma Registry, a project led by Dr. Isabelle Fleury at Hôpital Maisonneuve-Rosemont

Retrieved on: 
Thursday, December 16, 2021
Solution, HMR, Center, Population, Industry, AstraZeneca, Metabolism, C3I, Immunotherapy, Institute, Patient, Real, Leadership, Lymphoma, Lymphoproliferative disorders, RWE, GLOBE, GMP, Degenerative disease, Pharmaceutical industry

MONTREAL, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The C3i Center (C3i) is proud to announce the participation of AstraZeneca Canada (AstraZeneca) in supporting the development of the Lymphoma Registry.

Key Points: 
  • MONTREAL, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The C3i Center (C3i) is proud to announce the participation of AstraZeneca Canada (AstraZeneca) in supporting the development of the Lymphoma Registry.
  • C3i is delighted with the success of the Lymphoma Registry and thankful to receive AstraZeneca's support on this very important project which facilitates market access of innovative therapies, said Louisa Petropoulos, Chief Executive Officer of C3i.
  • We are grateful that AstraZeneca support our initiative to improve the care to patients with lymphoma, said Dr. Fleury.
  • AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide.

Real-World Evidence (RWE) Solutions Industry and Competition Landscape 2021-2026: Leading Players are IQVIA, ICON, PAREXEL, Oracle Corporation and Clinigen Group - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Biotechnology, Pharmaceutical, Health, Real-World Evidence, Global, Health information management, ICON, Conditional sentence, Population, IQVIA, Aetion, Degenerative disease, Decision-making, COVID-19, Cancer, PAREXEL, CAGR, Probability, Research, Drug development, Prevalence, Ageing, Obesity, Efficiency, Oracle Corporation, RWE, Diabetes, Animal, Pharmaceutical industry, Growth

The Global Real-World Evidence Solutions Market is expected to register a CAGR of 12.5% during the forecast period.

Key Points: 
  • The Global Real-World Evidence Solutions Market is expected to register a CAGR of 12.5% during the forecast period.
  • The contagious coronavirus has a potential economic impact and implications on most of the sectors, including the pharmaceutical industry.
  • Product launches, partnerships, collaborations, agreements, and market expansions are the key strategies adopted by players to grow and expand their presence in the real-world evidence solutions market.
  • Some of the key players in the market includes IQVIA, ICON, PAREXEL, Oracle Corporation and Clinigen Group among others.

ConcertAI Initiates Research Grant Program in Racial and Ethnic Health Disparities with Awards to UCSF and Case Western Reserve Researchers

Retrieved on: 
Thursday, December 16, 2021
Software as a service, RWD, Solution, FDA, List of life sciences, Research, History, Bladder cancer, Doctor of Philosophy, Diagnosis, Creativity, Prostate cancer, ERACE, Cancer, AI, LLC, CEO, Goal, Patient, Artificial intelligence, Health care, Case Western Reserve University, San Francisco, Program, Black, University, RWE, Customer success, DRS, Partnership, Precision medicine, Publication, University of California, San Francisco, Medical device, Medical imaging, Markt

Recipients were selected based on the impact, feasibility, and creativity of their research, along with their history of research projects and publications related to cancer disparities.

Key Points: 
  • Recipients were selected based on the impact, feasibility, and creativity of their research, along with their history of research projects and publications related to cancer disparities.
  • Dr. Washington will examine drivers of racial disparities in the management of advanced prostate cancer, leveraging RWD from ConcertAI that is linked to state-level measures of socioeconomic factors and healthcare resources.
  • To date, research has failed to examine how relationships between patients' personal factors, facility characteristics and regional healthcare resources exacerbate disparities for advanced prostate cancer.
  • "Any researcher with a computer can have open access to our tools to fuel future discoveries in cancer disparities research.